Citations 1
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Kumar, Shaji K., Adekola, Kehinde , Anderson, Larry , Costello, C. L., D’Angelo, Christopher R. , Elsedawy, Noura, Godara, Amandeep , Godby, Kelly, Hillengass, J, Holmberg, Leona, Htut, Myo , Huff, Carol Ann , Hultcrantz, Malin , Kang, Yubin , Larson, Sarah, Lee, Hans Chulhee, Liedtke, Michaela , Martin, Thomas, Omel, James, Robinson, Timothy J., Rosenberg, Aaron, Sherbenou, Daniel, Suvannasankha, Attaya, Valent, Jason , Varshavsky‐Yanovsky, Asya, Ye, J Christine, Kovach, Emily, Kumar, Rashmi , Kumar, Shaji , Callander, Natalie S. , Baljević, Muhamed , Baz, Rachid , Campagnaro, Erica , Costello, Caitlin , Derman, Benjamin A. , Devarakonda, Srinivas , Hillengass, Jens, Holmberg, Leona , Kang, Yubin , Larson, Sarah, Lee, Hans C. , Rosenberg, Aaron , Sarosiek, Shayna , Schroeder, Mark A. , Sherbenou, Daniel W , Suvannasankha, Attaya , Valent, Jason Neil , Vogl, Dan T. , Kovách, E
Journal of the National Comprehensive Cancer Network | January 8, 2026 | Volume: 24 | Issue: 1 | Pages: No page available
The treatment landscape for multiple myeloma (MM) is evolving rapidly and includes several new options. The management must be tailored to the individual. The NCCN Guidelines for MM provide a framework to base decisions regarding diagnosis, workup, treatment, and follow-up of both newly diagnosed and previously treated relapsed/refractory MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to newly diagnosed MM (NDMM).